Outcomes With Blinatumomab in Younger Adults With BCR:ABL1–negative B-ALL

Jonathan Webster, MD, and Nikesh Shah, MD, review data on the clinical activity of blinatumomab in younger adults with BCR::ABL1–negative B-cell ALL, focusing on remission depth and survival outcomes. They highlight how early integration of blinatumomab can enhance MRD clearance and potentially reduce the need for more intensive therapies. Webster and Shah also discuss emerging evidence suggesting particularly meaningful benefit in this younger patient population.